Synthesis of Novel Anticancer Agents, Antivirals and Small Biological Molecules
A special issue of Symmetry (ISSN 2073-8994). This special issue belongs to the section "Chemistry: Symmetry/Asymmetry".
Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 2671
Special Issue Editor
2.Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL 33620, USA
Interests: anticancer agents; antivirals; Parkinson’s disease; organic synthesis; drug design
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The global development of cancer registries has led to the discovery of novel drugs that derived from various sources that are used to treat several maladies including cancers and many viral diseases. About 80% of the world’s population depends on traditional therapeutics for several diseases, including anticancer and antiviral treatments. Many of these are symmetrical therapeutics (e.g., macrolides). The grouping together of antivirals, anticancer agents, and other small biological molecules from various sources in one review is not a matter of expediency, but follows from the increasing realization of the importance of the location as the most likely source of future “leads” in both areas. The currently available cancer and antiviral therapies still have various limitations, such as multi-drug resistance, undesired off-target effects, and unpredictable efficacies. The development of novel anticancer antiviral agents and other small biological molecules continues to be imperative to combat these diseases. The emerging molecular targets and signal pathways enable the development of novel strategies for the rational design of new anticancer agents, antiviral agents, and other small biologics. Numerous well-established synthetic methods and biological screening assays have paved the way for the discovery and development of new agents. Despite the availability of drugs in each area, more effective formulations are required. Some of these new drugs will undoubtedly come from natural products screening, in combination with synthetic modification, analog production, and combinatorial chemistry. In addition, the synthesis of other small biological molecules with specific disease targets are also welcome in this Special Issue of Symmetry. Both original research and review articles focusing on the rational design, synthesis, and/or biological evaluation of various anticancer and antiviral agents (including small molecules) as potential therapeutics are welcome to be submitted for publication in this Special Issue.
Prof. Dr. Ralph Salvatore
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Symmetry is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer agents
- antiviral agents
- drug design
- synthesis
- small biologics
